BRIEF REPORT

Peripheral precocious puberty: 46,XY complete gonadal dysgenesis

M. Santalha a,*, B. Amaral b, J. Pereira c, L. Ribeiro b, M. João Oliveira b, S. Figueiredo b, H. Cardoso b, C. Peixoto d, T. Borges b, J.A. Cidade-Rodrigues c

a Departamento de Pediatría, Centro Hospitalar do Alto Ave, Guimarães, Portugal
b Unidad de Endocrinología Pediátrica, Centro Hospitalar do Porto, Porto, Portugal
c Departamento de Cirugía Pediátrica, Centro Hospitalar do Porto, Porto, Portugal
d Departamento de Patología, Centro Hospitalar do Porto, Porto, Portugal

Received 27 May 2013; accepted 10 September 2013
Available online 17 September 2014

Abstract Despite standard clinical definitions and availability of diagnostic tests for precocious puberty, an intensive and structured investigation is needed in order to diagnose the aetiology in particular cases.
A 4-year-old, phenotypically female child was referred to paediatric endocrinology consultation for premature pubarche and thelarche. There was an acceleration of growth velocity with high levels of oestradiol and testosterone, and prepubertal FSH and LH measurements. Investigation showed bilateral gonadoblastoma as the cause of the peripheral precocious puberty.
Genetic studies revealed 46,XY karyotype with mutation c.89G>T (p.Arg30Ile) in exon 1 of the SRY gene, confirming the diagnosis of complete gonadal dysgenesis. Disorders of sexual differentiation must be considered in the approach and investigation of peripheral precocious puberty, especially in the presence of ovarian tumours, such as gonadoblastoma and dysgerminoma.

© 2013 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. All rights reserved.

KEYWORDS
Gonadal dysgenesis; Gonadoblastoma; Precocious puberty

PALABRAS CLAVE
Disgenesia gonadal; Gonadoblastoma; Pubertad precoz

Pubertad precoz periférica: disgenesia gonadal completa 46 XY

Resumen La pubertad precoz, a pesar de las definiciones clínicas estandarizadas y pruebas de diagnóstico disponibles, requiere, en ciertas situaciones una investigación exhaustiva y estructurada con el fin de conocer la causa.
Niña de 4 años de edad, fenotípicamente de sexo femenino, enviada a la consulta de endocrinología pediátrica por pubarquia y telarquia. Se observó aceleración en la tasa de...
Peripheral precocious puberty

crecimiento con niveles altos de estradiol y testosterona, con determinaciones prepúberes de la hormona luteinizante y foliculoestimulante. El resto del estudio de pubertad precoz periférica mostró la presencia de gonadoblastoma bilateral. El estudio genético reveló cariotipo 46 XY con mutación c.89G>T (p.Arg30Ile) en el exon 1 del gen SRY, confirmando el diagnóstico de disgenesia gonadal completa.

Los trastornos de la diferenciación sexual deben ser considerados en el abordaje y la investigación de las causas de la pubertad precoz periférica, especialmente en presencia de tumores de ovario, como gonadoblastoma y disgerminomas.
© 2013 Asociación Española de Pediatría. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

Precocious puberty (PP) is defined as the development of secondary sexual characteristics before the age of 8 years in girls and 9 years in boys.1,2

The aetiology of PP is diverse, ranging from variations of normal development, such as isolated premature thelarche, to diseases with significant comorbidity and mortality, such as germ cell tumours.

Addressing PP involves classifying it into two subtypes: central precocious puberty (CPP), which is gonadotropin-dependent (caused by early maturation of the hypothalamic–pituitary–gonadal [HPG] axis) and peripheral precocious puberty (PPP), which is gonadotropin-independent (due to excess secretion of sex hormones, androgens or oestrogens, from the adrenal glands, the gonads or exogenous sources).2

PPP may be of genetic origin (testotoxicosis; congenital adrenal hyperplasia; DAX1 gene mutation; McCune–Albright syndrome) or acquired (ovarian cyst; ovarian, testicular or adrenal tumours that produce the β subunit of human chorionic gonadotropin [β-hCG]; exogenous sex steroids).2

Acquired PPP occurs secondary to an increase in exogenous or endogenous sex steroids.

Diagnostic assessment includes an anamnesis and a detailed physical examination and additional tests, such as determination of basal and LHRH-stimulated gonadotropin levels (essential for differential diagnosis between CPP and PPP), hormone tests (testosterone, 17β-oestradiol, dehydroepiandrosterone sulphate [DHEA-S], androstenedione and 17-hydroxyprogesterone [17-OH-progesterone], β-hCG, free thyroxine [fT4] and thyroid-stimulating hormone [TSH]) and imaging tests (hand-wrist radiograph to determine bone age, pelvic or testicular and abdominal ultrasound and cranial MRI). Finally, in the presence of strong clinical suspicion, genetic testing should be performed.3

Case history

Girl referred to paediatric endocrinology consultation at the age of 4 years 2 months with suspected precocious puberty.

She had been born to term with adequate somatometry for her gestational age and no important family, perinatal or pathological history.

She presented with appropriate psychomotor development for her age and her height and weight development. Her weight was above the 95th percentile with upward centile crossing, having ranged from the 25th to the 50th percentile up to age 2 and then crossed to values above the 95th percentile by the age of 4 (Fig. 1).

Development of secondary sexual characteristics was observed at age 4, with the appearance of pubic hair and breast budding. In her first hospital assessment her weight was 22 kg (>95th percentile), height 115.5 cm (standard deviation score [SDS] 3.10), growth velocity 14.81 cm/year (SDS 7.13), target height 159 cm (SDS —0.50) and external female genitalia with Tanner stage A1-B2-P2.

Laboratory tests revealed high levels of oestradiol, total testosterone and β-hCG (Table 1).

The levels of 17-OH-progesterone, DHEA-S, delta-4-androstenedione, free T4, TSH, adrenocorticotropic hormone, cortisol (morning level), prolactin, lactate dehydrogenase (LDH) and alpha foetoprotein (α-FP) were normal for her age (Table 1). Serum FSH was 0.3 mU/mL and LH <0.1 mU/L, and the LH/RH test showed a prepubertal response (peak LH 1.1 mU/mL; peak FSH 2.3 mU/mL; LH/FSH ratio <1).

Bone age (BA) was 19 months in advance of chronological age (CA) (BA: 5 years 9 months, CA: 4 years 2 months). The pelvic ultrasound revealed a focal, well-circumscribed hyperechoic mass 25 mm in diameter in the left adnexal region. The pelvic computed tomography revealed bilateral solid adnexal lesions, with calcified matrix, measuring 30 mm on the right and 25 mm on the left.

Histological examination of the biopsy specimen showed patches of tissue occupied by bilateral gonadoblastoma structures, confirmed by immunohistochemistry (CD117 and inhibin-alpha).

A laparoscopic bilateral oophorectomy was performed. Anatomohistopathological analysis confirmed the presence of bilateral gonadoblastoma (Figs. 2 and 3).

Genetic testing of peripheral blood revealed a 46,XY karyotype with mutation c.89G>T (p.Arg30Ile) in exon 1 of the SRY gene (sex-determining region of the Y chromosome), which confirmed the diagnosis of complete XY gonadal dysgenesis due to a mutation in the SRY gene.

Discussion

Gonadoblastomas are rare benign tumours composed of germ cells mixed with circumscribed nests of sex cord cells, generally with a hyaline basement membrane and with diffuse or focal calcifications.4 They were first described by Scully in 1953.5
In 50% of cases there is excessive and abnormal growth of the germ cells, with progression to dysgerminoma, and occasionally other germ tumours, such as embryonic carcinoma and choriocarcinoma.\(^6\) These tumours are rarely causes of precocious puberty.\(^7\)

In this case, the onset of thelarche and pubarche at age 4, with a marked acceleration of growth velocity, was indicative of an organic condition as the cause of PP. The laboratory study showed high levels of oestradiol and testosterone, with prepubertal FSH and LH levels. These facts guided the analysis of peripheral causes. The pelvic assessment identified the presence of ovarian masses which, in conjunction with the high \(\beta\)-HCG level, suggested a tumoural condition as the diagnosis.

\(\beta\)-HCG is a glycoprotein hormone, which, as well as being associated with pregnancy, is considered a tumour marker.
for gynaecological cancer, and also, more rarely, for non-
gynaecological cancer. The tumours are hormonally active,
with the ability to produce β-HCG.9

Other possible germ cell tumour markers, such as LDH
and α-FP, were within normal values. Capito et al., in a
study carried out with 11 patients with 46,XY pure gonadal
dysgenesis, also described the presence of gonadoblastoma
and dysgerminoma with normal α-FP levels in a 17-year-
old patient with incomplete pubertal development for her
age.10

In the case presented here, the biopsy confirmed
a tumoural condition, which was identified as bilateral
gonadoblastoma.

These tumours occur almost exclusively in patients with
gonadal dysgenesis associated with the presence of a Y chromo-
osome, the most frequent karyotypes in these situations
being 46,XY and 45,X/46,XY mosaicism.8

Clinical presentation is variable, ranging from the
absence of symptoms to different degrees of virilisation or
feminisation and the presence of abdominal mass.11

Presentation with signs of precocious puberty seems to be
related to autonomous sex steroid secretion, which occurs
in 15% of cases, being conditioned by tumour components
derived from sex cord cells. Androgen secretion induces vir-
ilisation, or isosexual pseudopuberty, if oestrogen secretion
dominates.10

In this case, this strong association of gonadoblastomas
with disorders of sexual differentiation led us to carry out a
 genetic study, which confirmed the diagnosis of 46,XY com-
plete gonadal dysgenesis with the identification of mutation
c.89G>T (p.Arg30Ile) in exon 1 of the SRY gene. This mutation
was first described as a cause of gonadal dysgenesis by
Assumpção et al. in 2002.12

Complete gonadal dysgenesis is characterised by gonadal
streaks, normal development of the Müller ducts and
external female genitalia.10,13 This disruption of sexual
derdifferentiation is the result of a failure of foetal tes-
ticular development, secondary to mutations in certain
genes, such as SRY, SOX9, SF1, DAX1 and WT1.10,14 Mutations
of the SRY gene represent only 10–20% of 46,XY
 disorders of sexual differentiation, which is due in the
remaining cases to mutations in other genes among those
mentioned.13

Oophorectomy remains the treatment of choice due to
the high risk of malignant transformation.9

As well as oophorectomy, the treatment includes hor-
monal therapy and fertility induction, because of the
infertility of all these patients.

In conclusion, we wish to emphasise how important it is
for health care professionals to be familiar with the phys-
iology of normal puberty, so as to be able to recognise
anomalies in pubertal development, whose aetiology may
entail high morbidity and mortality, as in the case of ovarian
tumours.

**Conflicts of interest**

The authors have no conflicts of interest to declare.

---

**Table 1** Hormone values and tumour markers.

<table>
<thead>
<tr>
<th>Hormone</th>
<th>Result</th>
<th>Reference value</th>
</tr>
</thead>
<tbody>
<tr>
<td>17-Hydroxyprogesterone</td>
<td>90 ng/dL</td>
<td>4–115 ng/dL</td>
</tr>
<tr>
<td>Dehydroepiandrosterone sulphate</td>
<td>27.1 µg/dL</td>
<td>5–35 µg/dL</td>
</tr>
<tr>
<td>Delta-4-androstenedione</td>
<td>0.357 ng/mL</td>
<td>0.85–2.75 ng/mL</td>
</tr>
<tr>
<td>Free thyroxine</td>
<td>7.5 µg/dL</td>
<td>7.3–15 µg/dL</td>
</tr>
<tr>
<td>Thyroid-stimulating hormone</td>
<td>1.5 µU/mL</td>
<td>0.6–6.3 µU/mL</td>
</tr>
<tr>
<td>LH</td>
<td>297 ng/mL</td>
<td>16–396 ng/mL</td>
</tr>
<tr>
<td>FSH</td>
<td>15.5 pg/mL</td>
<td>7–28 pg/mL</td>
</tr>
<tr>
<td>Cortisol</td>
<td>7 µg/dL</td>
<td>3–20 µg/dL</td>
</tr>
<tr>
<td>Prolactin</td>
<td>13.5 mg/mL</td>
<td>2.6–18 mg/mL</td>
</tr>
<tr>
<td>Lactate dehydrogenase</td>
<td>257 U/L</td>
<td>110–295 U/L</td>
</tr>
<tr>
<td>Alpha-foetoprotein</td>
<td>1.6 mg/mL</td>
<td>0–15 mg/mL</td>
</tr>
<tr>
<td>β-HCG</td>
<td>10.3 U/L</td>
<td>≤1 U/L</td>
</tr>
<tr>
<td>FSH</td>
<td>0.3 mU/mL</td>
<td>&lt;5 mU/mL</td>
</tr>
<tr>
<td>LH</td>
<td>&lt;0.1 mU/L</td>
<td>&lt;5 mU/L</td>
</tr>
<tr>
<td>Oestradiol</td>
<td>17.3 pg/mL</td>
<td>&lt;12.5 pg/mL</td>
</tr>
<tr>
<td>Total testosterone</td>
<td>1.21 ng/mL</td>
<td>0.06–0.8 ng/mL</td>
</tr>
</tbody>
</table>

β-HCG: beta subunit of the human chorionic gonadotropin hormone; FSH: follicle-stimulating hormone; IGF1: insulin-like growth factor 1; LH: luteinising hormone.
References